OncoSignal
Live from Open Targets Platform, fetched 2026-11-12 00:03 UTC. Every row links to its source record.

RAD21 RAD21 cohesin complex component

ENSG00000164754 · protein coding · Open Targets profile

[Double-strand-break repair protein rad21 homolog]: As a member of the cohesin complex, involved in sister chromatid cohesion from the time of DNA replication in S phase to their segregation in mitosis, a function that is essential for proper chromosome segregation, post-replicative DNA repair, and the prevention of inappropriate recombination between repetitive regions (PubMed:11509732). The cohesin complex may also play a role in spindle pole assembly during mitosis (PubMed:11590136). In interphase, cohesins may function in the control of gene expression by binding to numerous sites within the genome (By similarity). May control RUNX1 gene expression (Probable). Binds to and represses APOB gene promoter (PubMed:25575569). May play a role in embryonic gut development, possibly through the regulation of enteric neuron development (By similarity). {ECO:0000250|UniProtKB:Q61550, ECO:0000250|UniProtKB:Q6TEL1, ECO:0000269|PubMed:11509732, ECO:0000269|PubMed:11590136, ECO:0000269|PubMed:25575569, ECO:0000305|PubMed:25575569}.

In 15 of 15 cancers, the evidence for RAD21 comes mainly from mutations found in tumours

Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.

Inherited (germline) variantsMutations in tumours (somatic)
00.250.50.751acute myeloid leukemiaacute myeloid leukemiaacute myeloid leukemia: somatic 0.60lung carcinomalung carcinomalung carcinoma: somatic 0.61bile duct carcinomabile duct carcinomabile duct carcinoma: somatic 0.61carcinoma of liver and intrahepatic bil…carcinoma of liver and intrahepatic biliary tractcarcinoma of liver and intrahepatic biliary tract: somatic 0.61endometrial endometrioid adenocarcinomaendometrial endometrioid adenocarcinomaendometrial endometrioid adenocarcinoma: somatic 0.61hepatobiliary neoplasmhepatobiliary neoplasmhepatobiliary neoplasm: somatic 0.61hemangioblastomahemangioblastomahemangioblastoma: somatic 0.61ovarian endometrioid adenocarcinoma wit…ovarian endometrioid adenocarcinoma with squamous differentiationovarian endometrioid adenocarcinoma with squamous differentiation: somatic 0.61breast carcinomabreast carcinomabreast carcinoma: somatic 0.46hepatocellular carcinomahepatocellular carcinomahepatocellular carcinoma: somatic 0.46squamous cell lung carcinomasquamous cell lung carcinomasquamous cell lung carcinoma: somatic 0.40urinary bladder carcinomaurinary bladder carcinomaurinary bladder carcinoma: somatic 0.46non-small cell lung carcinomanon-small cell lung carcinomanon-small cell lung carcinoma: somatic 0.46prostate carcinomaprostate carcinomaprostate carcinoma: somatic 0.46esophageal squamous cell carcinomaesophageal squamous cell carcinomaesophageal squamous cell carcinoma: somatic 0.46

Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.

Tractability

Small molecule
Structure with Ligand
PROTAC
UniProt Ubiquitination, Database Ubiquitination, Half-life Data

gnomAD loss of function constraint: o/e 0.2518700063228607 (upper bound 0.37349000573158264). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.

Who runs trials of these drugs

No named investigators on registry trials of RAD21's approved or late-stage drugs in the last three years.

No terminated, withdrawn or suspended trials of RAD21's drugs are registered

All 0 drugs and clinical candidates as a table

Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.

DrugTypeHighest stageIndicationsSource records
No drugs or clinical candidates recorded.